David Shaw’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

David Shaw’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,198	Closed	-$100K	–	5808
2021 Q3	$100K	Buy	+1,198	New	+$99.1K	﹤0.01%	4717
2016 Q4	–	Sell	-90	Closed	-$99K	–	3656
2016 Q3	$99K	Sell	90 -8	-8%	-$6.98K	﹤0.01%	3287
2016 Q2	$76K	Hold	98	–	–	﹤0.01%	3275
2016 Q1	$69K	Hold	98	–	–	﹤0.01%	3313
2015 Q4	$96K	Hold	98	–	–	﹤0.01%	3676
2015 Q3	$104K	Buy	98 +24	+32%	+$35.1K	﹤0.01%	3607
2015 Q2	$153K	Buy	74 +30	+68%	+$42.6K	﹤0.01%	3614
2015 Q1	$41K	Hold	44	–	–	﹤0.01%	3563
2014 Q4	$45K	Hold	44	–	–	﹤0.01%	3944
2014 Q3	$45K	Sell	44 -14	-24%	-$20.6K	﹤0.01%	4027
2014 Q2	$113K	Sell	58 -52	-47%	-$103K	﹤0.01%	4073
2014 Q1	$236K	Sell	110 -27	-20%	-$67.3K	﹤0.01%	4023
2013 Q4	$315K	Sell	137 -217	-61%	-$496K	﹤0.01%	4037
2013 Q3	$995K	Sell	354 -69	-16%	-$343K	﹤0.01%	3044
2013 Q2	$3.91M	Buy	+423	New	+$3.26M	0.01%	1543

Other funds holding ONCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

David Shaw's ONCT Position: Q4 2021 in Review

David Shaw sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2021, closing a stake of 1,198 shares — an estimated $100K sold.

David Shaw first reported a position in ONCT in Q2 2013 and held it in 15 quarters. The position peaked at $3.91M in Q2 2013. 82 funds tracked by Wall St. Rank hold ONCT as of Q4 2021.

David Shaw reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
David Shaw sold 1,198 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $100K.
David Shaw first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 15 quarters.
David Shaw's Oncternal Therapeutics, Inc. Common Stock position peaked at $3.91M in Q2 2013.
82 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2021.

Based on D.E. Shaw & Co's 13F filing for Q4 2021, filed 14 Feb 2022.